Antibody-drug conjugates are targeted cancer therapies that combine monoclonal antibodies with cytotoxic drugs to improve efficacy while minimizing toxicity. It accounts for a significant share of oncology drug development, offering better cancer therapies. The global cancer burden is projected to reach approximately 28.4 million cases by 2040. The growing focus on precision medicine, novel linker technologies, and improved payloads is driving ADC advancements. Factors, including rising cancer prevalence, increased R&D investments, and regulatory approvals, are accelerating market growth. The antibody drug conjugates pipeline analysis by Expert Market Research highlights various innovative treatment options that are expected to play a pivotal role in the future of cancer therapy. As the ADC pipeline continues to evolve, these therapeutics are set to revolutionize cancer treatment by offering targeted, more effective options for patients.
Major companies involved in the antibody-drug conjugates analysis include AstraZeneca, Oxford BioTherapeutics Ltd., Ambrx, Inc., and others.
Leading drugs currently in the pipeline include Trastuzumab Deruxtecan, FDA018-ADC, ARX788, and others.
The antibody drug conjugates pipeline is expanding owing to the growing focus on precision medicine, the rise in cancer prevalence, and the need for more effective treatments.
The Antibody Drug Conjugates Pipeline Analysis Report by Expert Market Research gives comprehensive insights into antibody-drug conjugates therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for antibody-drug conjugates. The antibody-drug conjugates report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The antibody-drug conjugates pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with antibody-drug conjugates treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to antibody-drug conjugates.
Antibody-drug conjugates (ADCs) are targeted therapies that combine monoclonal antibodies with cytotoxic drugs. They bind specifically to tumor-associated antigens, delivering potent agents directly to cancer cells while minimizing systemic toxicity. ADCs represent a breakthrough in precision medicine, offering improved efficacy and safety over traditional chemotherapy. Their evolving design drives advancements in personalized cancer care.
Breast cancer is among the diseases treated with ADCs. These therapeutics deliver cytotoxic agents directly to malignant cells by targeting overexpressed antigens, reducing collateral damage to healthy tissues. ADCs are also used in hematologic malignancies and other solid tumors. As of January 2024, 12 antibody-drug conjugates (ADCs) had been approved by the FDA, addressing 16 different indications, including various forms of breast cancer, bladder cancer, non-small-cell lung cancer, as well as classic and non-Hodgkin lymphoma, among others. By targeting specific antigens on cancer cells, ADCs offer a precise treatment approach that enhances therapeutic effectiveness while reducing side effects, making them an essential component of modern oncology care.
This section of the report covers the analysis of antibody-drug conjugates drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I covers a major share of the total antibody-drug conjugates clinical trials. Phase I constitutes the highest share in the disease market pipeline at 44.98%. Meanwhile, Early Phase I, Phase II, Phase III, and Phase IV currently hold shares at 1.06%, 39.16%, 14.29%, and 0.53%, respectively, offering promising opportunities for future development.
The drug molecule categories covered under the antibody-drug conjugates pipeline analysis include monoclonal antibodies, cytotoxic payloads, and linkers. The antibody-drug conjugates report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for antibody-drug conjugates.
Recent improvements in monoclonal antibodies for antibody-drug conjugates (ADCs) include targeting new cancer markers like HER2 and Nectin-4 and using better linkers to deliver drugs more effectively. FDA-approved ADCs like Enhertu and Padcev are helping treat cancers like breast and bladder cancer. New approaches also combine ADCs with immune therapies for better results.
The EMR report for the antibody-drug conjugates pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed antibody-drug conjugates therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in antibody-drug conjugates clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for antibody-drug conjugates. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of antibody-drug conjugates drug candidates.
Trastuzumab Deruxtecan, sponsored by AstraZeneca, is a targeted anti-HER2 antibody-drug conjugate designed to deliver cytotoxic agents directly to cancer cells. It is a part of a Phase IV study, which is assessing its safety in Indian patients with unresectable or metastatic HER2-positive breast cancer. The study is expected to be completed by October 2026 projecting promising safety outcomes.
FDA018-ADC is a novel antibody-drug conjugate that is actively targeting the Trop2 receptor in cancer cells. It binds to overexpressed Trop2, internalizing into tumor cells, and releasing a potent cytotoxic payload to induce cell death. Developed by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., the ADC is demonstrating promising efficacy for triple-negative breast cancer treatment. It is being further evaluated in a phase III clinical trial.
ARX788 is a HER2-targeted antibody-drug conjugate being developed for HER2-positive metastatic breast cancer patients previously treated with T-DXd. It combines a monoclonal antibody with the cytotoxic payload AS269 using proprietary technology, allowing precise conjugation. The Phase II study is examining ARX788’s safety and efficacy through Q3W IV infusions, aiming to provide improved outcomes.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Antibody Drug Conjugates Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for antibody-drug conjugates. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into antibody-drug conjugates collaborations, regulatory environments, and potential growth opportunities.
Global Antibody Drug Conjugates Market Report and Forecast
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share